These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new research shows. Compared to another common ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...

Chronic health conditions are having a serious, negative impact on the welfare of the country's workers and their output, a ...

A new study breaks down several cases of Ozempic blindness, linked to semaglutide and tirzepatide. Here's what could be ...

More than 36 million Americans have type 2 diabetes, a condition primarily attributed to the body's cells not responding to ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...